Clinical Trials Logo

Urinary Bladder Cancer clinical trials

View clinical trials related to Urinary Bladder Cancer.

Filter by:

NCT ID: NCT06307704 Recruiting - Prostate Cancer Clinical Trials

Lung US for PEEP Optimization in Robotic Radical Prostatectomy or Cystectomy Patients

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

There is an increasing trend in the use of robotic-assisted radical prostatectomy or cystectomy (RARPC). Preventing lung atelectasis without inducing overdistention of the lung is challenging. Many studies tried to optimize PEEP titration by using methods such as dead space fraction guided and static pulmonary compliance directed techniques, or by using electrical impedance tomography. However, the use of these methods is limited by inaccuracy and the need for sophisticated devices. Bedside Lung ultrasound is fast, easy and economic technique that is gaining interest in the operating room. Ultrasound-guided PEEP titration has been used in bariatric surgeries (different position and usually shorter procedure time) and proved effective in improving oxygenation, compliance and reducing the incidence of postoperative pulmonary atelectasis and hypoxia without causing hemodynamic instability. The aim of this study is to evaluate the effectiveness of intraoperative individualized lung ultrasound-guided stepwise PEEP optimization in patients undergoing RARPC on oxygenation, intraoperative and early postoperative pulmonary complications.

NCT ID: NCT06156787 Completed - Clinical trials for Urinary Bladder Cancer

Patterns of Urinary Bladder Cancer in Darfur, Suda

Start date: November 1, 2020
Phase:
Study type: Observational

Background: Bladder cancer (BC) exhibits extreme heterogeneity regarding clinical outcome, etiology, histology, and geographic distribution. Recent clinical observations point to alterations in the BC pattern in the Sudan, possibly as a result of lifestyle changes brought on by the enormous migration from rural to urban locations. This study aimed to identify the pattern of bladder cancer in Darfur. Patients and Methods: A cross sectional, hospital-based study, it was conducted inNyala specialized hospital, during the period from (2020 to 2022), included one hundred and five patients with bladder mass matching the inclusion criteria were studied over the diversity of demographic data , clinical finding, pathological type and possible risk factors .

NCT ID: NCT06115434 Recruiting - Clinical trials for Urinary Bladder Cancer

Comparing Operative, Postoperative and Quality of Life of Patients After Salvage and Radical Cystectomy

Start date: January 30, 2015
Phase:
Study type: Observational [Patient Registry]

To compare operative difficulties, type of urinary diversion, intraoperative & postoperative complications and quality of life in patients underwent radical cystectomy and those after salvage cystectomy.

NCT ID: NCT05946369 Completed - Clinical trials for Urinary Bladder Cancer

Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer

Start date: May 1, 2020
Phase:
Study type: Observational

There is a relation between inflammatory cells and the prognosis of tumors (cancer colon, renal, liver, and urinary bladder). In this study, the investigators will link the Neutrophils to Lymphocytes ratio to the response to intravesical BCG therapy post trans-urethral resection of urinary bladder tumors for the non-invasive urinary bladder tumors.

NCT ID: NCT05822934 Recruiting - Clinical trials for Urinary Bladder Cancer

Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer

Start date: November 1, 2022
Phase: Phase 3
Study type: Interventional

Patients will be randomized in 1:1 ratio to two treatment groups first group will receive 3-4 cycles of neoadjuvant Carboplatin(AUC4)-Gemcitabine (treatment group) and second group will receive 3-4 cycles of neoadjuvant Cisplatin(75mg/m2 Day1)-Gemcitabine (Control group). Patients will undergo radiological assessment, full laboratory work up, and cystoscopy before undergoing either radical cystectomy or Definitive Radiotherapy concurrent with chemotherapy

NCT ID: NCT05787938 Not yet recruiting - Clinical trials for Urinary Bladder Cancer

Role of MRI in Assessment of the Urinary Bladder Wall Post Transurethral Tumor Resection

Start date: April 1, 2023
Phase:
Study type: Observational

To study the feasibility of using magnetic resonance imaging (MRI) in evaluation UB wall thickening after transurethral resection (TUR) of bladder cancer.

NCT ID: NCT05644041 Recruiting - Clinical trials for Urinary Bladder Cancer

Intravesical Gemcitabine in Patients With NMIBC

Start date: March 1, 2023
Phase: Phase 2
Study type: Interventional

Intravesical immunotherapy or chemotherapy for non-muscle invasive bladder cancer is a well-established treatment for preventing or delaying tumor recurrence after bladder tumor resection. For high-risk non-muscle invasive bladder cancer, immunotherapy in the form of intravesical Bacillus Calmette-Guérin (BCG) can be effective as first-line, nevertheless, the response rate to BCG is suboptimal with many patients failing treatment. Following BCG-failure, however, very few effective therapeutic options exist besides life-changing cystectomy. In addition, nationwide shortages of BCG have pushed the use of alternative intravesical therapies for non-muscle invasive bladder cancer. At Banner University Medical-Tucson, the use of intravesical Gemcitabine is considered as standard treatment for patients with bladder cancer who are unable to get BCG or have failed prior BCG treatment. The role of Gemcitabine as treatment for NBMIC is poorly understood. The purpose of this study is to gain a better understanding of the use of Gemcitabine intravesical chemotherapy for non-muscle invasive bladder cancer in a prospective cohort of patients.

NCT ID: NCT05621837 Recruiting - Breast Cancer Clinical Trials

Quantifying Systemic Immunosuppression to Personalize Cancer Therapy

Serpentine
Start date: March 10, 2022
Phase:
Study type: Observational

The Serpentine (Stratify cancER PatiENTs by ImmuNosupprEssion) project, represents the most consistent effort so far attempted to translate MDSC into clinical practise by producing an off-the-shelf compliant assay for quantifying these cells in peripheral blood.

NCT ID: NCT05335707 Withdrawn - Clinical trials for Urinary Bladder Cancer

Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy

Start date: September 14, 2022
Phase:
Study type: Observational

This single arm pilot study will evaluate the feasibility and acceptability for perioperative Comprehensive Geriatric Assessment (CGA) and CGA-directed supportive and restorative care for patients with muscle-invasive bladder cancer who are planned to undergo preoperative chemotherapy.

NCT ID: NCT05072600 Recruiting - Bladder Cancer Clinical Trials

Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer

Start date: December 7, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase II, single-arm, study of pembrolizumab as maintenance therapy in muscle-invasive bladder cancer (MIBC) participants who have received maximum TURBT and tri-modality treatment (TMT) and achieved CR. All participants will receive pembrolizumab monotherapy per 21 days no longer than 17 cycles until disease progression or death.